CytoSorbents year-end letter to shareholders

In a letter to shareholders released today, CytoSorbents (OTCBB: CTSO) CEO Dr. Phillip Chan reviews the company’s major milestones for 2011, highlighted by the first-ever product revenue from the launch of its CytoSorb blood purification therapy to treat sepsis in Europe. Dr. Chan also outlines the company’s numerous opportunities and goals for 2012 and 2013, including [...]

CytoSorbents encouraged by market reception of CytoSorb

CytoSorbents (OTCBB: CTSO), which two months ago began a controlled market release for CytoSorb, its therapy to reduce cytokine storm in septic shock, is very encouraged by the market reception so far, CEO Dr. Phillip Chan said in the third quarter report. “The response at both the German Sepsis Society Congress and the European Society [...]

CytoSorbents releases additional sepsis data

CytoSorbents (OTCBB:CTSO) has released additional data from its recently completed European sepsis trial using CytoSorb, a first-in-class extracorporeal cytokine filter approved for use in the European Union. Analysis of clinical data from the European trial in patients with severe sepsis or septic shock in the setting of lung injury suggests that CytoSorb treatment has a [...]

2011 could be transition year for CytoSorbents

As its European clinical trial for CytoSorb approaches the finish line, CytoSorbents (OTCBB:CTSO) hopes to transition from a development-stage company to a commercial-stage company in 2011. “If things go well, our goal is to hopefully obtain European CE Mark regulatory approval for CytoSorb as a cytokine filter sometime in the first half of this year [...]

Spectral to sell Toraymyxin in Canada

Spectral Diagnostics (TSX:SDI) has signed a long-term, exclusive distribution agreement with Toray Industries and Toray Medical of Japan to market and sell in Canada Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. The product and Spectral’s EAA diagnostic, which measures endotoxin and identifies patients for treatment, are already [...]

Spectral starts U.S. trial of Toraymyxin

Spectral Diagnostics (TSX:SDI) has initiated its U.S. pivotal trial of Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, for patients with severe sepsis. The EUPHRATES trial will study standard of care versus standard of care and Toraymyxin directed by Spectral’s Endotoxin Activity Assay (EAA), an FDA cleared assay for use in sepsis. [...]

Riding the Next Wave

No, we’re not talking about the north coast of Maui but rather a new research platform from long-time biotech analyst David Martin of Dundee Securities. “If I’m going to recommend that investors own a basket of biotech stocks, it makes sense that I ought to initiate on a basket of stocks rather than make one-off [...]